Evidence map›Paper›PMID 33124720›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2020

Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies.

Sook Wah Yee, Dina Buitrago, Adrian Stecula, Huy X Ngo, Huan-Chieh Chien, Ling Zou, Megan L Koleske, Kathleen M Giacomini

Open access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Sook Wah YeeDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Dina BuitragoDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Adrian SteculaDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Huy X NgoDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Huan-Chieh ChienDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Ling ZouDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Megan L KoleskeDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Kathleen M GiacominiDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
University of California, San Francisco · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7M
West Coast Central Comprehensive Metabolomics Resource Core (WC3MRC)U24DK097154 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FIEHN, OLIVER · 2012 to 2017
$9.9M
Equipment Supplement for Discovery of Pharmacogenomic Biomarkers for OATP1B1 and OATP1B3R01GM117163 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FLOREZ, JOSE CARLOS, HEDDERSON, MONIQUE MARIE · 2015 to 2023
$5.5M
Drug-Vitamin Interactions Mediated by the Thiamine Transporter, SLC19A3R01DK108722 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M, GREENBERG, ANDREW S · 2017 to 2020
$2.6M
Biomarkers of Dietary Intake and Exposure Data Coordinating CenterU24DK129557 · NIDDK · DUKE UNIVERSITY · PI CHAKRABORTY, HRISHIKESH · 2021 to 2025
$2.6M
NCI NIH HHS P30 CA082103NIDDK NIH HHS R01 DK108722NIDDK NIH HHS U24 DK097154NIDDK NIH HHS U24 DK129557NIGMS NIH HHS R01 GM117163
6 · The paper itself

Abstract

The human solute carrier 22A (SLC22A) family consists of 23 members, representing one of the largest families in the human SLC superfamily. Despite their pharmacological and physiological importance in the absorption and disposition of a range of solutes, eight SLC22A family members remain classified as orphans. In this study, we used a multifaceted approach to identify ligands of orphan SLC22A15. Ligands of SLC22A15 were proposed based on phylogenetic analysis and comparative modeling. The putative ligands were then confirmed by metabolomic screening and uptake assays in SLC22A15 transfected HEK293 cells. Metabolomic studies and transporter assays revealed that SLC22A15 prefers zwitterionic compounds over cations and anions. We identified eight zwitterions, including ergothioneine, carnitine, carnosine, gabapentin, as well as four cations, including MPP

Indexed as

Biological TransportCarnitineCarnosineCell LineErgothioneineGabapentinGenomicsHEK293 CellsHumansLigandsOrganic Cation Transport ProteinsPhylogenyTransfectionCarnitineCarnosineErgothioneineGabapentinLigandsOrganic Cation Transport ProteinsSLC22A15 protein, humancarnitinecarnosineergothioneinemetabolomictransporter

Identifiers

PMID33124720
PMCPMC7839234
OpenAlexW3095806681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.